News

Meta-analysis suggests iron therapy lowers the risk of heart failure hospitalization and cardiovascular death in patients with chronic kidney disease.

Bruckner discusses her team’s long-term data on the safety and efficacy of birch bark extract, also known as Oleogel-S10, for those with epidermolysis bullosa.

A study found distinct DNA methylation patterns at birth linked to early-onset atopic dermatitis by age 2. Findings will be presented at AAAAI 2025.

In this quiz, we test your knowledge of evidence-based management strategies, recommended epinephrine doses, and evolving guidance on patient follow-up and discharge planning for anaphylaxis.

These findings were from a 52-week analysis of a Phase-2 trial in participants with chronic spontaneous urticaria.

Olpasiran sustained reductions in oxidized phospholipids on apoB in patients with ASCVD and elevated Lp(a) levels in the Phase 2 dose-ranging trial.

In these new findings, investigators highlight phase 1 research into ritlecitinib for patients aged 6 to 12 years with alopecia areata.

New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.

A study found 1 in 7 children with anaphylaxis experience biphasic reactions after epinephrine, with no recurrences after 4 hours, highlighting corticosteroid impact.

Avapritinib 25mg daily significantly improved quality of life (QoL), disease control, and basal serum tryptase (BST) levels.

Iron administration was linked to a decrease in platelet counts, even in the absence of preexisting thrombocytosis.

These data point to inaccessibility, distance from providers, and insurance-related barriers as obstacles to mental health improvement among children with atopic dermatitis.

A pooled analysis of LIBERTY-CSU CUPID Study A and Study C showed dupilumab reduces itch in patients with chronic spontaneous urticaria by week 24.

The analysis of 2004-2024 Google Trends data revealed varying levels of public interest in IgAN, MD, FSGS, LN, and DN.

CELZ-201 reduced insulin dependency and stabilized HbA1c in 1-year follow-up data from the AlloStem pilot study in T2D.

In this retrospective analysis, investigators in Japan highlighted the prevalence and incidence of comorbidities in those with atopic dermatitis, psoriasis, alopecia areata, and vitiligo.

Children with urticaria or angioedema face greater risks of adverse events after COVID-19 vaccination, but most tolerate subsequent doses with proper management.

An approval for sparsentan in focal segmental glomerulosclerosis would mark the second rare kidney disease approval for the agent.

Exposure to aspirin and NSAIDs was linked to a reduced risk of cancer incidence and overall mortality in patients with chronic liver diseases.

Data from the CAFETERIA trial provide insight into exposure vs avoidance strategies for high-threshold peanut allergy.

Cardiovascular hospitalization rates were higher in the US than in Denmark, driven by a significant increase in heart failure and myocardial infarction hospitalizations.

An analysis found anaphylaxis following non-COVID vaccines is rare, with greater rates for yellow fever and influenza vaccines.

Test your knowledge of the 2023 Anaphylaxis Update from the Joint Task Force on Practice Parameters, focusing on diagnoses and biomarkers!

Barnes explains the significance of having mirikizumab as a treatment option for Crohn’s disease and reviews new VIVID-2 open-label extension data.

The drug given this designation, known as rezpegaldesleukin, is indicated for adult and pediatric patients aged 12 years and older with atopic dermatitis.

Boehringer plans to soon submit a new drug application for nerandomilast for treating PPF to the FDA.

Announced by LIB Therapeutics Inc., the agency has set a PDUFA target action date of December 12, 2025.

This announcement by INmune Bio, Inc., follows positive findings in the MissionEB clinical trial evaluating CORDStrom for treatment of recessive dystrophic epidermolysis bullosa.